Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
AssigneeAlderbio Holdings LLC
InventorsJeffrey T.L. SMITH, John A. Latham, Mark Litton, Randall Schatzman
Life of this patent
Estimating the term…
Abstract
The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
Claims16
1-76. (canceled)
A method of treating cachexia, weakness, fatigue, and/or fever in a patient diagnosed with an interleukin-6 (IL-6) associated disorder, comprising (1) administering to the patient an anti-IL-6 antibody or antibody fragment comprising a variable light (VL) polypeptide comprising CDR polypeptides having the amino acid sequences of SEQ ID NO:4, 5 and 6, or (ii) and a variable heavy (VH) polypeptide comprising CDR polypeptides having the amino acid sequences of SEQ ID NO:7, 8 or 120 and 9, and (2) detecting cachexia, weakness, fatigue, and/or fever in the patient before, during or after antibody administration.
Dependencies are inferred from the claim text.